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Abstract 
Among the numerous autoimmune diseases associated with various H L A alleles, the one 
wi th the highest relative risk so far reported has been ankylosing spondylitis wi th HLA-B27 . 
To examine this relationship more directly, we have cloned the gene encoding the HLA-B27 
antigen and determined its complete D N A sequence. Comparison of the HLA-B27 sequence 
wi th that of the allelic H L A - B 7 shows a high level of homology. Mutations are distributed 
evenly between exons and introns. Exon 1 and intron 1 are the most divergent ones, and the 
degree of divergence distinctly declines towards the 3' end. The H L A - B 2 7 gene when 
transfected into murine L cells is expressed on the cell surface and reacts with a panel of 
monoclonal antibodies directed against monomorphic and polymorphic determinants associ-
ated with H L A - B 2 7 antigen. 
The isolation of this gene allows for the first time a search for structural features which make 
the H L A - B 2 7 antigen a high risk genetic factor for a group of rheumatoid disorders, in 
particular ankylosing spondylitis. 
Introduction 
Among the numerous H L A markers associated with various human 
diseases, the HLA-B27 antigen is a clear exception. This allelic glycopro-
tein, present in the cell membrane of all nucleated cells, represents an 
unusually high-risk factor for its carriers, conveying susceptibility for a 
group of joint diseases of which ankylosing spondylitis (AS) is the most 
prominent. Pooling all data on Caucasians, one arrives at a relative risk of 
more than 70.0 for individuals carrying the HLA-B27 antigen (1). Recent 
Abbreviations: AS = ankylosing spondylitis; bp = base pair; kb = kilo bases; mAb = 
monoclonal antibody; Tc = cytotoxic T cell; tk = thymidine kinase. 
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studies have been directed towards elucidating the biochemical structure of 
the HLA-B27 antigen (2, 3). So far, no differences between the HLA-B27 
antigens present in healthy and AS patients have been found. Even the 
subdivision of HLA-B27 into several antigen subtypes (4) did not indicate 
any structural differences between the HLA-B27 molecules from healthy 
and affected individuals. 
In order to investigate the mechanisms of H L A involvement in disease, in 
general, and the nature of the HLA-B27 and AS association in particular, 
we isolated the gene encoding the HLA-B27 antigen. In this paper we 
describe the expression of the HLA-B27 gene in murine L-cells and present 
the complete D N A sequence of the gene encoding the HLA-B27 polypep-
tide together with its deduced complete amino acid sequence. The genomic 
organization of the HLA-B27 gene is compared with a cross-reactive allele, 
the homologue H L A - B 7 gene, which exhibits no significant disease associa-
tion. 
Materials and Methods 
Isolation of the HLA-B27 gene 
A genomic library was constructed with the vector pTCF (5, 6 ) from peripheral white blood 
cells of a healthy individual with the H L A type: HLA-A2/2 , -B5/27, -Cw2/3. The cosmid 
library was screened with an H L A - B locus specific c D N A probe derived from the 3'untrans-
lated region of the H L A - B 8 gene (7). 
DNA sequence analysis 
D N A sequence analysis of the three B g l l l fragments containing the entire HLA-B27 gene 
subcloned in the vector p U C l 3 was carried out mostly by the dideoxy sequencing method (8) 
and partly, to verify ambiguous nucleotides, by the chemical sequencing procedure (9). The 
sequencing strategy is shown in Figure 1. 
Transfection of cosmid clone CD2.6 into murine Ltk~ cells 
Murine thymidine kinase negative (tk~) cells, L D l (H-2 k ) were transformed with cosmid 
D N A and the herpes tk gene contained in the vector pOPF (5), using the calcium phosphate-
mediated D N A transfer technique (10). Populations of transformed cells were selected using 
hypoxanthine-aminopterin-thymidine ( H A T ) selection, and stable L t k + transformed clones 
were established. The human lymphoblastoid cell line LG-2 ( H L A - A 2 , 2 ; B27/27; Cwl/1) was 
used as a positive control for HLA-B27 expression. 
Monoclonal antibodies (mAb) 
The origin and characteristics of the mAbs used are listed in Table 1. 
Immunofluorescence staining and cytofluorography 
Cell surface antigen expression by L cells was studied by EPICS analysis (EPICS V, Coulter 
Electronics). Monolayer cultures of L cells were harvested by 1 m M PBS/EDTA and washed 
three times in PBS, 0.1 % Na Azide, 10% FCS. Approximately 10 5-10 6 cells were incubated 
with 50 u.1 of culture supernatant or ascitic fluid (1:105) of monoclonal antibodies. After 1-h 
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Fig. 1. Restriction map of the cosmid clone CD2.6, fine restriction map of the HLA-B27 locus 
and sequence strategy. 
Top line: Restriction map for the cosmid clone CD2.6 encoding the HLA-B27 antigen. The 
following restriction sites are shown: K = K p n l ; S = Sali; X = X h o l . Middle line: The fine 
restriction map of the HLA-B27 locus, t = B g l l l ; T = K p n l ; ? = PstI; 7 = PvuII ; T = 
Sacl. Above the restriction map is shown the position of the exons and the 3' untranslated 
region (3' ut). 
a) sequences determined by the dideoxy sequencing method (8). 
b) sequences obtained by the chemical sequencing procedure (9). 
incubation, cells were washed and stained with 50 j i l of fluorescein-conjugated goat anti-
mouse IgG + IgM (Jackson Immunoresearch Laboratories, Inc.). Fluorescence intensity was 
measured by flow microfluorimetry by analyzing 1-2 x 104 stained cells. Fluorescence data for 
the expression of HLA-B27 antigen on the transfected L cells are expressed as fluorescence 
intensity relative to the L cell of the native H - 2 k phenotype. 
Table 1. Characteristics of the monoclonal antibodies used 
Monoclonal"" 
antibodies 
Ig class Specificity References 
W6/32 IgG2a anti H L A - A , B , C 20 
11-4.1 IgG2a anti H - 2 k 21 
MPC11 IgG2b undefined 22 
K T l I gM anti H L A - A 23 
MA2.1 IgG, anti H L A - A 2 , B17 24 
ME1 IgG, anti H L A - B 7 , B27, B22 25 
BB7.1 IgG, anti H L A - B 7 26 
B27M2 I g M anti HLA-B27 , Bw47 2 
* Monoclonal antibodies ref. 20-26 were derived from culture supernatants and were gifts 
from Dr . J . P. Johnson. Antibody B27M2 (Ascites, 1:105) was a gift from Dr . F. C. Grumet. 
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Results 
Genomic organization of the HLA-B27 gene 
The entire HLA-B27 gene is contained in the cosmid clone C D 2.6. The 
restriction map of the cosmid clone and the gene, itself contained in three 
Bgl l l fragments, is shown in Figure 1. No other class I gene was located 
within a distance of 6 kb to the left side and of 30 kb to the right side of the 
HLA-B27 locus. Since this cosmid clone contains only one H L A class I 
gene, it was used directly for the gene transfer experiments. 
Expression of the human HLA-B27 antigen in murine cells transformed 
with the cloned HLA-B27 gene (CD2.6) 
We have introduced cosmid C D 2.6 (see Fig. 1) together with the herpes 
simplex virus thymidinekinase (tk) gene into mouse L tk~ (of H-2 k 
haplotype) cells using calcium phosphate D N A transfer. We tested the tk 
3 
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Fig. 2A and B. EPICS-Analysis: Reactivity of the L D l cell line (Fig. 2A), and the transfection 
clone 2.6 (Fig. 2B) with different anti-H-2 and an t i -HLA monoclonal antibodies. Fig. 2A 
represents the fluorescence profiles of the L D l cell line (H-2 k ) with the mouse plasmocytoma 
antibody MPC-11 and monoclonal antibodies W6/32 ( H L A - A , B, C) and 11-4.1 (H-2 k ) . Fig. 
2B shows the reactivity pattern of the transfection clone 2.6 with the same Moabs MPC-11, 
W6/32 and 11-4.1. The fluorescence profiles were obtained by analysing 2 x 10 4 cells. 
Fluorescence intensity was assessed by flow microfluorimetry by using integral amplification. 
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Table 2 :\ Binding of anti-H-2 and ant i -HLA antibodies to the mouse L cell line L D l , the 
mouse L cell transfectant 2.6 and the human B cell line LG-2 
Fluorescence 
% pos. intensity 
Cell Ant ibody Specificity cells (median) 
L D l _ 1.7 4.3 
L D l 11-4.1 H - 2 k 95.1 140.0 
L D l M P C l l undefined 3.4 5.8 
L D l W6/32 H L A - A , B , C 2 4.3 
2.6 1.4 4.8 
2.6 11-4.1 H - 2 k 98.0 150.0 
2.6 MPC11 undefined 2.3 5.1 
2.6 W6/32 H L A - A , B , C 96.0 50.0 
2.6 KT1 H L A - A 1.4 4.6 
2.6 MA2.1 H L A - A 2 , B17 1.9 4.6 
2.6 M E 1 H L A - B 7 , B27, B22 95.0 40.4 
2.6 BB7.1 H L A - B 7 2.3 4.8 
2.6 B27.M2 HLA-B27 , Bw47 9.3 10.4 
LG-2 _ 3.0 9.1 
LG-2 W6/32 HLA-A,JB,C 88.0 173.0 
L G - 2 11-4.1 H - 2 k 2.0 6.3 
LG-2 MPC11 undefined 4.0 8.2 
LG-2 K T 1 H L A - A 60.0 41.8 
LG-2 MA2.1 H L A - A 2 , B17 68.0 47.7 
LG-2 M E 1 H L A - B 7 , B27, B22 58.8 138.1 
LG-2 BB7.1 H L A - B 7 18.0 11.3 
LG-2 B27.M2 HLA-B27 , Bw47 49.5 90.0 
::" The results are representative of several different experiments 
positive clones for expression of H L A class I cell surface antigens, using 
monoclonal antibody binding in immunofluorescence assays. 
The results of the binding assays are shown in Figure 2 and Table 2. All 
clones derived from the CD2.6 transformation bind anti-HLA class I 
monomorphic antibody (W6/32) at a level comparable with the endogenous 
H-2 antigen expression. The level of H L A antigen detected was 30-50 % of 
that of the H - 2 k antigen. 
These assays demonstrate that L cells transformed with cosmid CD2.6 
expressed a cell-surface polypeptide which is recognized by W6/32, while 
the untransformed cells were completely negative. To characterize the 
HLA-antigen encoded by the clone CD2.6 we used several monoclonal 
reagents directed against H L A antigens of the donor from whom the 
cosmid library was constructed (see Table 2). The H L A - A 2 allele was 
excluded, since the monomorphic anti-HLA-A monoclonal antibody, K T l , 
and monoclonal antibody MA2.1, which reacts with H L A - A 2 , did not bind 
to the transfectant clones (or gave signals comparable to the M P C l l 
control). The cosmid clone CD2.6 did bind, however, two monoclonal 
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antibodies directed against HLA-B27. The reagent M E l binds to the 
transfectants at the same level as W6/32. This binding is not due to cross-
reactivity with HLA-B7 , since binding of BB7.1 was negative. The mono-
clonal antibody B27.M2, which recognizes a subset of HLA-B27 antigens, 
also binds to the transfectant clones, although at a much lower level. This 
reagent is strongly positive for a B cell line derived from the individual from 
whom CD2.6 was isolated. The lower binding of this mAb to the trans-
fected L cell may be due to the combination of xenogeneic ß 2 microglobulin 
with the HLA-B27 polypeptide. The expression of transfected HLA-B27 
gene in the murine cells is increased twofold after incubation with lym-
phognes present in a supernatant derived from rat spleen cells stimulated 
with Concanavalin A (data not shown). These data show that cell lines 
transformed with cosmid CD2.6 express a cell-surface antigen with a 
specificity which is indistinguishable from the HLA-B27 antigen of the 
positive control B cell line LG-2 (HLA-A2,2; B27/27). We therefore 
conclude that the clone CD2.6 codes for the HLA-B27 antigen. 
We tried to determine whether the presence of the HLA-B27 molecule 
on the murine cells could render these cells as targets for allogeneic 
cytotoxic T cell (T c cell)-mediated killing by human T c cells raised against 
the HLA-B27 antigen. Thus far, however, human anti-B27 T c cells did not 
lyse the transfectant L cell clones significantly (data not shown). It was 
reported previously that murine L cells expressing H L A class I genes are 
poor targets for human allogeneic T c cells (11, 12), whereas other trans-
fected murine cells expressing H L A class I antigens can be lysed by human 
allogeneic T c cells (12). 
General structure of the HLA-B27 gene 
The overall structure and dimensions of the HLA-B27 gene are the same 
as those of other reported H L A genes. The HLA-B27 gene consists of eight 
exons and seven introns. Table 3 shows that the majority of the exons are of 
the same length as those of the H L A - B 7 (14) and H L A - A 2 (14, 15) genes. 
The sequence of cloned HLA-B27 cDNA derived from the L G 2 line, which 
we reported recently, confirms these exon assignments (16). The approxi-
mate size of the introns is the same in all three genes, with only minor 
variations in the exact lengths. 
DNA sequence of the HLA-B27 gene 
We determined the D N A sequence of the entire HLA-B27 gene. The 
sequencing strategy is shown in Figure 1. The complete D N A sequence 
together with the deduced amino acid sequence of the HLA-B27 antigen is 
shown in Figure 3. 
The sequence of the HLA-B27 gene is similar to that of other human 
class I genes reported earlier (14-19). For the first time, determination of 
the exact length of exon 1 could be made from the sequence of this H L A -
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Table 3. Sequence comparison of class I genes 
Region 
H L A -
Length (bp) 
-B27 B7 b A2 C B27/B7 
% divergence3 
B27/A2 A2/A3 H - 2 K b / H - 2 K d 
5' region 517 507 526 8.1 10.2 10.6 nd 
exon 1 73 73 73 10.9 15.0 4.1 7.8 
intron 1 129 123 129 9.3 12.4 10.9 3.7 
exon 2 270 270 270 5.2 10.7 3.0 10.3 
intron 2 241 245 240 5.4 9.5 3.3 4.3 
exon 3 276 276 276 6.1 8.3 4.7 11.2 
intron 3 575 575 599 1.0 15.8 7.7 4.0 
exon 4 276 276 276 0.4 10.1 4.0 6.1 
intron 4 92 92 97 1.1 20.6 3.1 4.7 
exon 5 117 117 117 0.8 14.5 2.6 5.8 
intron 5 442 442 436 2.2 14.5 5.0 3.9 
exon 6 33 33 33 0 12.2 3.0 6.0 
intron 6 106 106 142 1.9 16.9 2.1 2.3 
exon 7 48 48 48 0 12.5 2.1 2.6 
intron 7 182 182 169 2.7 23 4.7 1.8 
8 + 3' ut 424 422 405 1.8 nd 0.5e 5.0 
3' flanking 209 209 160 1.9 nd 5.5 4.0 
a Insertions and deletions were counted as one change 
b The sequence of Biro et al. (14) 
c The sequence of Koller et al. (15) 
d The comparison of Weiss et al. (29) 
e Calculated for 165 bps of the H L A - A 2 gene 
nd = not determined 
B27 gene. All other H L A class I genes published to date contain two in 
frame initiation codons (see Fig. 4) which would result in two possible 
leader peptides of 21 and 24 amino acids. HLA-B27 contains only the first 
A T G with an exon 1 of 49 base pairs. The gene contains the 3.5 kb Taq I 
fragment, a previously described restriction fragment length polymorphism 
which was assigned to the HLA-B27 gene (27). The fragment was detected 
by using an H L A class I cDNA probe. The Taq I fragment spans the 3' half 
of the HLA-B27 gene. The detection of this HLA-B27-specific gene band 
becomes easier when a probe derived directly from this region or an H L A -
B locus specific probe is used. 
Potential Alternative Splicing Signals in the HLA-B27 gene. Recently, an 
alternative intron/exon organization affecting the second exon has been 
proposed for the H-2K d gene (28). In a cDNA clone, apparently derived 
from a processed H-2K d transcript, an alternative splice acceptor site in the 
first intron, 50 nucleotides 5' to the usual acceptor site, is used. In addition, 
an extra intron is created by the splicing out of a D N A segment of exon 2, 
coding for the amino acids 6-38 of the classical H-2K d antigen. Until now it 
could not be shown whether this alternative splice site is used in vivo 
yielding a polypeptide that is synthesized from this alternative mRNA 
transcript. 
l u Pro S e r S e r C l n S e r T h r Val Pro l i e V a l G l y l i e Val Ala C l y Leu I I a Val Leu A l a Val Val Val H e C l y 
ACCACCCCTTCACCAGGTCACGGCCCCTCATCTTCCCTTCCTTTCCCAC AG CCC TCT TCC CAG TCC ACC CTC CCC ATC GTG CCC ATT GTT OCT GGC CTG OCT CTC CTA CCA CTT GTC CTC ATC CCA 
A l a Val V a l A l a Ala T a l n e t Cys Arg Arg L y s S e r S e r G 
GCT GTC GTC OCT CCT CTG ATC TGT ACC AGG AAG ACC TCA C GTACGGAACGGGTGAGGCGTCCCCTCTCAGTTTTCTTGTCCCACTCGCGGTTTCAACCCCCACCTACAAGTGTTCCCTCCCTCATTACTCCCAACCA 
GCATCCACACACCGGCTAACGCACCCTCGCACCCTGTGTCCCACCACTTACTCTTTTCTGCACCACATCTCACAATCAACCACCCATGTATCACCTTCGTGGTTCTCGTGTTCGGGTCCTCATTCCACCATTCATGACTCACCGGAACCTC 
CCTGCTAAGCACAGACCTTAGGACCGCAGTTGCTCCAGCACCCACACTTCCTTTCCTCGTCTTTCCTGATCCTGCCTTGGGTCTGTAGTCATACTTCTGCAAATTCCTTTTGGGTCCAACACGACCAGGTTCCTCTAACATCTCATGCCCC 
GACCTCACTCTCTCGCATCAACTTCTCCCTCATCACTTTCCCTACACAACATCCAIGACCACÄCCTAAGCACTCACACGCAGGCAGTCCACTTCACCGACAGGCATTCCACCACCACiAGTGAACGCGAACCCGCTCCCCGCCACTCCCC , $ 0 
CTCTCTCCCTGGTTTCCACAGACACATCCTTGTCCCGGACTCAGCCAGACAGTCTCACAAACACGCTGGTGTAGCACA ACACGGATCAGCACGAACGTCCAAGCCCCCGGCCGCGCTCTCAGCCTCTCAGCCTCCGACACCCTTCTCTGC 
ATTGGCGACGCGCACAGTTCCGGATTCCCCACTCCCACGAGTTTCACTTCTTCTCCCAACCTATGTCGGCTCCTTCTTCCiCGATACTCCTGACCCGTCCCCATTTCCCACTCCCATTGGGTCTCGCCTCTCT AGAGAACCCAATCACTC 1,53 
« e t Arg V a l T h r A l a Pro Arg T h r Leu Leu Leu Leu Leu T r p G l y A l a Val A l a Leu Thr G l u 
TCGCCCCGCTCCCACTTCTAAAGTCCCCACCCACCCACCCCCACTCACAATCTCCTCACACGCCGAC ATC CCC CTC ACC CCC CCC CCA ACC CTC CTC CTG CTG CTC TCC CCC GCA CTG CCC CTC ACC GAG 588 
T h r T r p A l a C l y S e r 
ACC TCC GCT C GTGAGTCCCCGCTCAGCCAGCGAAATCCCCTCTCTCCCGACCAGCCACGCCACCCACGCCCCGGCGCAGCACCCGCGGAGCCCCCCCCGCACCACGGTCCCGCCGCTCTCACCCCCTCCTCCCCCCCAC CC TCC 72M 
H i s S e r « e t Arg T y r Phe H i s T h r S e r T a l S e r Arg Pro C l y Arg C l y C l u P r o Arg Phe l i e T h r Val C l y T y r V a l Asp Asp Thr Leu Phe Val Arg Phe Ala S e r Asp Ala L, 
CAC TCC ATC AGG TAT TTC CAC ACC TCC CTC TCC CCC CCC CCC CCC CCG CAC CCC CGC TTC ATC ACC GTG CCC TAC CTG CAC CAC ACC CTG TTC CTC AGG TTC CAC ACC CAC CCC 838 
03 
A l a S e r Pro Arg G l u G l u Pro Arg Ala Pro t r p l i e G l u C l n C l u C l y Pro G l u T y r T r p Asp Arg G l u T h r G i n l i e Cys L y s A l a Lys A l a C l n Thr Asp Arg G l u Asp Leu PI 
CCG ACT CCG AGA CAC CAC CCC CCC CCG CCG TCC ATA CAC CAC GAG CGC CCG CAC TAT TCC CAC CCC GAG ACA CAC ATC TCC AAG CCC AAG GCA CAG ACT GAC CCA CAC GAC CTC <J$2 
Arg T h r Leu Leu Arg T y r T y r Asn C l u S e r C l u A l a C 
CCG ACC CTC CTC CGC TAC TAC AAC CAC ACC CAC CCC C CTGACTCACCCCCCCCCCGCCGCACCTCACGACTCCCCATCCCCCACCTACGGCCCGCCTCCCCCCCÄGTCTCCGGCTCCGÄCATCCCCCCCCGAGCCCG i e ß 9 
CCCCACCCGCCCACACCCTCCACCCCCCACACCCCACGCGCCTTTACCCCCTTTCATTTTCACTTCACGCCAAAATCCCCCCCGTTGGTCCCCCCGCCCCGCGGCTCGGGCCdCACCCGGCTGACCCCCGGCCCCCCTCCAC ^ 
l y S e r B i s T h r Leu C l n Asn « e t T y r C l y C y s Asp V a l G l y Pro Asp C l y Arg Leu Leu Arg C l y T y r H i s G i n Asp A l a T y r Asp G l y L y s Asp T y r l i e A l a Leu Asn G l u 2 
GC TCT CAC ACC CTC CAG AAT ATC TAT CCC TCC CAC CTC CCC CCC CAC CGC CCC CTC CTC CCC CCG TAC CAC CAG GAC CCC TAC CAC GGC AAG CAT TAC ATC CCC CTC AAC CAG 1 3«3 v> 
Asp Leu S e r S e r T r p Thr Ala A l a Asp T h r A l a A l a G i n H e T h r G i n Arg L y s T r p C l u A l a A l a Arg V a l A l a C l u C l n Leu Arg A l a T y r Leu G l u C l y C l u Cys Val C l u ^ 
GAC CTG ACC TCC TGG ACC CCC CCG CAC ACG CCG CCT CAG ATC ACC CAG CGC AAG TCC GAG GCC CCC CGT GTG GCG CAC CAG CTC AGA GCC TAC CTG GAG CCC CAG TCC CTG CAG 1«»S7 
!* 
T r p Leu Arg Arg T y r Leu G l u Asn C l y L y s C l u T h r Leu C l n Arg A l a A 




sp Pro Pro L y s T h r B i s V a l T h r B i s B i s Pro H e S e r Asp H i s C l u A l a T h r Leu Arg Cys T r p A l a Leu C l y Phe T y r Pro ^ 
AGAGATGCAAAGCGCCTCAATTTTCTCACTCTTCCCATCAG AC CCC CCA AAG ACA CAC GTC ACC CAC CAC CCC ATC TCT GAC CAT CAC CCC ACC CTG ACC TCC TCC CCC CTC CGC TTC TAC CCT 21 bu Q : 
PS 
A l a C l u H e T h r Leu T h r T r p C l n Arg Asp C l y C l u Asp C l n T h r C l n Asp T h r C l u Leu Val C l u T h r Arg Pro A l a C l y Asp Arg T h r Phe C l n L y s T r p A l a A l a Val Val 2j 
GCG CAC ATC ACA CTC ACC TGC CAC CCC GAT CCC CAC GAC CAA ACT CAC CAC ACT GAC CTT GTC CAG ACC ACA CCA GCA CCA CAT ACA ACC TTC CAG AAC TCC CCA CCT GTC CTC 22?8 PI 
T a l Pro S e r G l y C l u C l u C l n Arg T y r T h r Cys H i s Val C l n B i s C l u G l y Leu Pro L y s Pro Leu T h r Leu Arg T r p G ^ 
GTG CCT TCT GCA CAA GAG CAC AGA TAC ACA TCC CAT CTA CAC CAT CAC CGG CTC CCC AAC CCC CTC ACC CTC ACA TGG G GTAAGGACCCGCATCAGCCCTCATATCTCTTCTCACCCAA ACC 2U80 
> z 
l y C l y L y s C l y G l y S e r T y r S e r G i n A l a A l a C 
T C C T T C C T C C C A C T C C C C T C A C A C G C A A A T T T T C T T C C C A C A C CT CCA AAA G C A GCC ACC T A C TCT CAC C C T GCC T G T A A G T G A T G C G G G T C G G A C T G T G G A G G A G C T C A C C C A C C C C C T A A T T C C T C C T G T C C C A C G 3103 p 0 
y s S e r Asp S e r A l a C l n C l y S e r Asp Val S e r Leu T h r A l a S T O P £j 
T C T C C T G C G C C C T C T G A C C A C G T C C T C T T T T T C T T C T A C T C C A C CC ACC G A C A C T CCC C A G CCC TCT C A T CTC TCT CTC ACA CCT T C A AAA G C T C A C A T T C T T C C C C T C T A C A C T C C C T C C C C T G G C A C C T C T 3230 X 
G G C C C T C C C T C C C G C A C T C C C C A A A C C C C T C C C T A A T C C A C A T T C T T T C A T T C C C A T C T T T C C C C T C T C T G C T G C C C T C T T T A C A C T C T C A T C A C T T A C C A T C A C T A A C C A C A A T T T C T T C A T G A C T C T T G T T T T C T C T A C C C T C A C A C 2 
A C C T G T C T T G T G A C G G A C T G A G A T C C A C G A T T T C T T C A C C C C T C C C C T T T C T C A C T T C A A C A C C C T C T C C C A T C T C T T T C T C C A A A C C C A C C T C A A T G T C T C T C C G T C C C T C T T A C C A T A A T G T C A C C A C G T C C A G A G A C C A G C C C A C C C 3535 Q 
C C G T C T C C A C T C T G A C C C C T C T T C C C A T G C T G A C C T G T G T T T C C T C C C C A C T C A T C T T T C C T C T T C C A C A C A C C T C C G C C T C G A T G T C T C C A T C T C T C T C T C A A C T T T A T C T C C A C T C A C C T G C A A C T T C T T A C T T C C C T A C T C A A A A T A p 
A G A A T C T G A A T A T A A A T T T C T T T T C T C A A A T A T T T C C T A T C A C A G C T T C A T G G A T T A A T T A A A T A A G T C A A T T C C T C G A A T T T C A G A C A C C A A A T A A A C A C C T C A C A A C C T T C C A G A A T C T G C A T C T T C G C T C T G C T C A C T C T G T T C C A C 38 35 rr j 
C T C G C C T G T C C A G A A G G C T C T G C C C C G C C C A G T C T G C A C C C C C C T C T G C C C A T T T C G T G T T C A C T C C A T C A T C G C C T T T A T C T C C T T A C T C C T C A C C T C C C T C A C C T T C A C T C C T C C A T T C T C C T T G T C C C T T C A C T C C A A A C G T T G T C C jo 
A C C G C G A C C T G T C A C C A C A C A G C C T C A C A C l<ei 5 
ig. 3. Nucleotide sequence of the H L A - B 2 7 gene. Nucleotides are numbered from the Sac I site. The promotor ( T C T A A A ) and the polyadenylation 
( A A T A A A ) signals are underlined. Splice sites and potential alternative splice signals are indicated by lines. The amino acids are placed above the triplets of 
he exons in the three letter code. 
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Inspection of the HLA-B27 gene sequence reveals several alternative 
splice sites (AG/G) only a few of which do not result in stop codons. The 
alternative splice acceptor sites described for the H-2K d gene are found in 
exactly the same positions in the HLA-B27 gene (659 and 831, marked in 
Fig. 3) together with the corresponding donor site in exon 2 at position 736. 
The additional exon would code for 26 amino acids as in the H-2K d gene. A 
similar alternative transcript cannot be generated from the H L A - B 7 gene. 
The presence of potential alternative splice signals in the HLA-B27 gene 
raises the question of whether they might be used. No cDNA clone coding 
for HLA-B27 has been described that is the product of an alternative 
spliced transcript (16). 
A complete c D N A sequence coding for the HLA-B27 antigen (16) and 
potential peptide sequencing data for this antigen (3) have been published 
recently. We, therefore, do not discuss the protein sequence in detail. It is of 
interest to note that the genomic sequence for the HLA-B27 antigen 
contains the triplet G C G at amino acid position 182 coding for alanine, as it 
was found by protein sequencing (3). The cDNA clones, derived from a 
homozygous B cell line, code for a valine (GTG) in this position. A second 
amino acid replacement change is found in the leader at amino acid position 
7 where the cDNA clone codes for a glutamine (GAG), due to a change of 
three nucleotides. Another additional nucleotide is found in the 3'untrans-
lated region at position 3692. The insertion of a T destroys the Taq I site 
found in the c D N A (16). This Taq I site is in so far important, because the 
LG2 line from which the cDNA clones were derived cannot contain the 
polymorphic Taq I fragment of 3.5 kb. Its corresponding fragment must be 
of 1800 bp. The five changes are the only differences found between the 
c D N A sequence and the genomic D N A sequence. Since both genes code 
for the same HLA-B27 subtype (HLA-B27.1), we conclude that this might 
be the first evidence for somatic mutations in B cell lines in a gene other 
than immunoglobulin. 
Comparison of the gene sequence of HLA-B27 with an allelic gene sequ-
ence. The comparison of the two H L A - B alleles, HLA-B27 and the cross-
reactive H L A - B 7 , at the gene level shows a high degree of nucleotide 
sequence conservation in both coding (exons) and non-coding regions 
(introns), as well as in the flanking regions (Table 3). The highest level of 
divergence is expressed in intron 1 and exon 1, which is not contained in the 
mature H L A molecule. The degree of divergence is highest in the 5' half of 
the gene (exon 1 to exon 3). The HLA-B27 and H L A - B 7 genes are virtually 
identical in the 3'part of the genes. Surprisingly, the exons and introns have 
accumulated mutations to a similar degree. 
The sequence comparison of exon 2 of the two alleles (Fig. 4) reveals that 
most of the mutations are scattered. Only one cluster of changes is found to 
the 3' end of this exon, from amino acid position 77 to 83. 
COMPARISON: 
E x o n 1: 
MET ARG VAL THR ARG PRO ARG THR L E U L E U L E U L E U L E U TRP G L Y ALA VAL ALA L E U THR GLU THR TRP ALA 
H L A - B 2 7 ATG CGG GTC ACG GCG C C C CGA ACC C T C C T C CTG CTG C T C TGG GGG GCA GTG GCC CTG ACC GAG ACC TGG GCT 
B 7 T T G C C C C C 
A2 GCC T G A C T C C G 
8 0 9 0 
GLU ASP L E U ARG THR L E U L E U ARG TYR TYR ASN GLU S E R GLU ALA 
H L A - B 2 7 GAG GAC C T G CGG ACC C T G C T C CGC TAC T A C AAC CAG AGC GAG GCC 
B7 AG A G G 
A2 T G G G 
Fig. 4. Sequence of the HLA-B27 gene of exon 1 (leader) and exon 2 (1st domain) compared to equivalent regions in the H L A - B 7 (14) and H L A - A 2 (15) 




E x o n 2: 1 10 20 w 
G L Y S E R H I S S E R MET ARG T Y R PHE H I S THR S E R VAL S E R ARG PRO G L Y ARG G L Y GLU PRO ARG PHE I L E THR VAL y> 
H L A - B 2 7 GGC T C C CAC T C C ATG AGG TAT T T C CAC ACC T C C GTG T C C CGG C C C GGC CGC GGG GAG C C C CGC T T C ATC ACC GTG ^ 
B7 T T A ^ 
A2 T T T A G A g 
Z 
3 0 4 0 5 0 p 
G L Y T Y R VAL ASP ASP THR L E U PHE VAL ARG PHE ALA S E R ASP ALA ALA S E R PRO ARG GLU GLU PRO ARG ALA PRO ^ 
H L A - B 2 7 GGC T A C GTG GAC GAC ACG C T G T T C GTG AGG T T C GAC AGC GAC GCC GCG AGT CCG AGA GAG GAG CCG CGG GCG CCG O 
B7 C A Z 
A2 A C C A G AT ? 
6 0 7 0 r 
TRP I L E GLU GLN GLU G L Y PRO GLU T Y R TRP ASP ARG G L U THR GLN I L E C Y S L Y S ALA L Y S ALA GLU THR ASP ARG | 
H L A - B 2 7 TGG ATA GAG CAG GAG GGG CCG GAG TAT TGG GAC CGG GAG ACA CAG ATC TGC AAG GCC AAG GCA CAG ACT GAC GCA 
B7 A C A C 
A2 T G G AA GTG C T C 
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Discussion 
We have shown that the cosmid clone CD2.6 contains one H L A class I 
gene which is the HLA-B27 gene. This human H L A gene can be expressed 
in murine L cells and is recognized by monoclonal anti-HLA reagents even 
when the heavy chain is combined with murine ß 2 microglobulin. Several 
monoclonal antibodies demonstrate that the epitopes, normally associated 
with the HLA-B27 molecule, are present on the surface of the transformed 
L cells. 
The D N A sequence and deduced amino acid sequence of the HLA-B27 
antigen were compared to the D N A sequence of its allele HLA-B7 . As we 
have discussed elsewhere (16), the polypeptide structure exhibits some 
replacement changes unique to the HLA-B27 antigen. Among them two 
mutations are unusual: position 67 is occupied by a cysteine and position 
131 by a serine. The change in position 131 generates a new restriction site, 
G A G C T C , which is recognized by the enzyme Sacl. These changes could 
be decisive in the peculiar role of HLA-B27 as a risk factor for ankylosing 
spondylitis. 
Surprisingly, the comparison of the D N A structure of the HLA-B27 
gene with its allele H L A - B 7 revealed a high degree of homology between 
the two genes. This is interesting in two aspects: Firstly, the HLA-B27/B7 
pair is another example of human class I alleles showing a greater degree of 
nucleotide conservation than allelic class I genes in the mouse (15, 29). 
Thus, the two murine alleles H-2K b and H-2K d have a much lower level of 
homology in the polymorphic exons 2 and 3 (10.3 and 11.2% divergence, 
respectively), whereas the introns show the same degree of homology as the 
human alleles (see Table 3). This higher mutation rate in the H-2K genes 
could be due to their position centrometric to the I-A region, thus possibly 
making it a preferred target for gene conversion events. This explanation is 
supported by the sequences of H-2 class I genes other than H-2K. The 
sequence comparison of the H - 2 D b gene with its proposed allele H - 2 L d (30) 
(H-2D d being less homologous) shows a level of divergence comparable to 
human H L A - A and H L A - B alleles. Another explanation for the fact that 
the human class I alleles are more similar than their murine homologues 
could be based on the different evolution in the two species. It remains to be 
explained why human class I alleles exhibit quite a high degree of diverg-
ence at the 5' half of the gene (exon 1 and intron 1). 
The second aspect of interest concerns the differences found between the 
HLA-B27 and H L A - B 7 genes. The two H L A - B alleles are as homologous 
as the H L A - A alleles and show to the 3'end of the gene, i.e. exon 4 to 3' 
untranslated region, an even higher level of homology. This fact makes it 
difficult to assign the cause for the association of HLA-B27 with certain 
diseases to particular structural features of the HLA-B27 gene. Surpris-
ingly, the highest degree of divergence is found in exon 1 and intron 2. The 
leader peptide, encoded by exon 1, is cleaved off during maturation of the 
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H L A class I molecule. The sequence of intron 2 is not part of the mRNA 
and therefore not translated. Only in case of an alternative processed 
transcript of the HLA-B27 gene involving intron 2 could this sequence be 
of importance. 
Several hypotheses have been proposed to explain the association of some 
H L A alleles with certain diseases. The isolation and expression of the gene 
encoding the HLA-B27 antigen allows us to address the proposed mechan-
ism with recombinant D N A techniques. Since we isolated the gene from a 
so far healthy individual, we cannot rule out the highly unlikely possibility 
that the HLA-B27 gene of a patient might contain mutations. T R A P A N I et 
al. (31) isolated a 3.5 kb Taq I fragment containing the 3'half of a supposed 
HLA-B27 gene from a spondylitic patient. The partial sequence of 180 bps, 
derived from intron 6-exon 7-intron 7 presented in this report, is identical 
to our sequence, except the G at position 3223 in intron 7 is lacking in their 
sequence but is contained in the H L A - B 7 gene. 
To examine the possibility that a putative «illness susceptibility» gene in 
linkage disequilibrium with HLA-B27 is responsible for the diseases associ-
ated with this antigen (the two-gene theory; see ref. 1 for review) we have 
begun chromosomal walking experiments starting from the HLA-B27 gene, 
in order to compare the organization of the HLA-B27 haplotype with other 
extended H L A - B loci. 
The molecular mimicry hypothesis (the one-gene theory; see ref. 1 for 
review) postulates that the molecular structure of infectious agents are 
similar to those of the H L A antigens on the cell surface. In vitro 
mutagenesis experiments may be helpful in defining HLA-B27 specific 
epitopes that may cross-react with bacterial proteins. At present, we are 
converting the HLA-B27 unique replacement changes at amino acid posi-
tions 67 and 131 back to the «wildtype» configuration. Then we can 
analyze whether these mutations affect the overall structure of the molecule 
defined by monoclonal antibodies and human allogeneic cytotoxic T cells. 
In summary, this paper describes the isolation of the HLA-B27 gene 
which, for the first time, allows the investigation of the mechanisms 
underlying the observed association between HLA-B27 and various dis-
eases. 
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